Clene Secures $10 Million Debt Facility to Advance ALS Drug Development
Clene Inc. has obtained a new $10 million debt facility to support the development of its lead drug candidate CNM-Au8 for amyotrophic lateral sclerosis (ALS). This funding will enable the company to generate additional data requested by the FDA for a potential accelerated approval pathway.
Read the full story























